IP Library Granted Patent US 10,213,765
Granted Patent B2
US 10,213,765 · App. 15/603,285 · Granted Feb 26, 2019

Chromatography ligand comprising domain C from

Inventors: Martin Hall (Uppsala, SE); Sture Larsson (Uppsala, SE); Andreas Muranyi (Uppsala, SE); Gustav Rodrigo (Uppsala, SE); Jinyu Zou (Uppsala, SE); Per-Mikael Aberg (Uppsala, SE)
Assignee: GE Healthcare Bioprocess R&D
B01J20/24B01D15/3809B01J20/285B01J20/286B01J20/289B01J20/28019B01J20/3212B01J20/3219B01J20/3274B01J20/3293C07K1/22C07K14/31C07K16/00C07K17/00C07K17/10B01J2220/52B01J2220/54C07K2317/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,213,765
App. No.
15/603,285
Granted
Feb 26, 2019
Kind
B2
Abstract

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

Claims (34)

1. A chromatography matrix comprising:

a solid support; and

a ligand coupled to the solid support, the ligand comprising at least two polypeptides,

wherein the amino acid sequence of each polypeptide comprises at least 55 contiguous amino acids of a modified SEQ ID NO. 1, and

wherein the modified SEQ ID NO. 1 has an alanine (A) instead of glycine (G) at a position corresponding to position 29 of SEQ ID NO. 1.

2. The chromatography matrix of claim 1 , wherein the ligand comprises 2-8 of the polypeptides, optionally coupled via linker segments.

3. The chromatography matrix of claim 1 , wherein the chromatography matrix has retained at least 95% of its original binding capacity after 5 hours incubation in 0.5 M NaOH.

4. The chromatography matrix of claim 1 , wherein the ligand is capable of binding to the Fab part of an antibody.

5. The chromatography matrix of claim 1 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s).

6. The chromatography matrix of claim 5 , wherein the terminal group comprises arginine or cysteine.

7. The chromatography matrix of claim 1 , wherein the ligand is coupled to the solid support via thioether bonds.

8. The chromatography matrix of claim 1 , wherein the ligand further comprises one or more other alkaline-stable protein-based units.

9. The chromatography matrix of claim 1 , wherein the solid support is a polysaccharide.

10. The chromatography matrix of claim 1 , wherein the solid support is comprised of substantially spherical particles.

11. The chromatography matrix of claim 1 , wherein the solid support is porous.

12. The chromatography matrix of claim 1 , wherein the ligand comprises an amino acid sequence that comprises 2-8 of the polypeptides.

13. The chromatography matrix of claim 1 , wherein the solid support comprises two or more ligands.

14. A chromatography matrix comprising:

a solid support; and

a ligand coupled to the solid support, the ligand comprising at least two polypeptides,

wherein the amino acid sequence of each polypeptide comprises at least 55 amino acids in alignment with SEQ ID NO. 1, and

wherein each polypeptide has an alanine (A) instead of glycine (G) at a position corresponding to position 29 of SEQ ID NO. 1.

15. The chromatography matrix of claim 14 , wherein the ligand comprises 2-8 of the polypeptides, optionally coupled via linker segments.

16. The chromatography matrix of claim 14 , wherein the chromatography matrix has retained at least 95% of its original binding capacity after 5 hours incubation in 0.5 M NaOH.

17. The chromatography matrix of claim 14 , wherein the ligand is capable of binding to the Fab part of an antibody.

18. The chromatography matrix of claim 14 , wherein the ligand comprises a terminal coupling group comprising at least one nitrogen and/or sulfur atom(s).

19. The chromatography matrix of claim 18 , wherein the terminal group comprises arginine or cysteine.

20. The chromatography matrix of claim 14 , wherein the ligand is coupled to the solid support via thioether bonds.

21. The chromatography matrix of claim 14 , wherein the ligand further comprises one or more other alkaline-stable protein-based units.

22. The chromatography matrix of claim 14 , wherein the solid support is a polysaccharide.

23. The chromatography matrix of claim 14 , wherein the solid support is comprised of substantially spherical particles.

24. The chromatography matrix of claim 14 , wherein the solid support is porous.

25. The chromatography matrix of claim 14 , wherein the ligand comprises an amino acid sequence that comprises 2-8 of the polypeptides.

26. The chromatography matrix of claim 14 , wherein the solid support comprises two or more ligands.

Assignments (3)
CHANGE OF NAME Recorded Oct 8, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054034/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2018
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 046395/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2017
From: HALL, MARTIN; LARSSON, STURE; MURANYI, ANDREAS; RODRIGO, GUSTAV; ZOU, JINYU; ABERG, PER-MIKAEL
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 042484/0106 →
Priority Claims (1)
SE 0602061 · Sep 29, 2006 · national
Continuity (5)
Continuation 15063471 · Mar 7, 2016
Division 14164519 · Jan 27, 2014
Continuation 13559663 · Jul 27, 2012
Division 12443001
Related Publication 20170259244A1 · Sep 14, 2017
Cited By (2)
US 12,337,293 US 12,679,873